Biocon Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Biocon Pharma Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $112.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biocon Pharma Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $112.4M Trade | TransData Nexus

Product Portfolio — Top 8 by Export Value

Biocon Pharma Limited exports 8 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Calcium	Vitamins & Supplements	$43.3M	865	4.8%	5
2	Rosuvastatin	Cardiovascular	$32.6M	652	7.0%	4
3	Atorvastatin	Cardiovascular	$11.4M	229	1.1%	12
4	Esomeprazole	Gastrointestinal	$9.4M	188	2.1%	7
5	Magnesium	Vitamins & Supplements	$9.4M	188	2.6%	4
6	Omeprazole	Gastrointestinal	$5.0M	101	0.8%	11
7	Tacrolimus	Immunosuppressants	$1.1M	22	0.5%	7
8	Everolimus	Immunosuppressants	$250.0K	5	0.7%	3

Biocon Pharma Limited exports 8 pharmaceutical products across 4 therapeutic categories with a total export value of $112.4M. The top category is Vitamins & Supplements (46.8% of portfolio), followed by Cardiovascular (39.2%), indicating a concentrated portfolio with the top 5 products accounting for 94.3% of total export value.

Biocon Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, was incorporated on October 31, 2014, under the Corporate Identification Number (CIN) U24232KA2014PLC077036. The company is headquartered in Bengaluru, Karnataka, India, at 20th KM, Hosur Road, Bengaluru – 560100. Biocon Pharma Limited specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of March 2023, Biocon Limited, the parent company, employed approximately 16,545 individuals. Biocon Pharma Limited's website is accessible at www.biocon.com.

2Manufacturing Facilities

Biocon Pharma Limited operates five state-of-the-art manufacturing facilities across India, located in Bengaluru, Hyderabad, and Visakhapatnam. These facilities are designed to manufacture high-quality products efficiently and reliably. The manufacturing plants are approved by various international regulatory bodies, including the US FDA, EMA, COFEPRIS, TGA, and ANVISA. The facilities are equipped with advanced technologies such as microbial fermentation, chemical synthesis, peptide synthesis, and high-potent active pharmaceutical ingredients (HPAPIs) production.

3Key Leadership

Biocon Limited, the parent company of Biocon Pharma Limited, is led by a team of experienced executives. Kiran Mazumdar-Shaw serves as the Executive Chairperson, guiding the company's strategic direction. Siddharth Mittal holds the position of Chief Executive Officer and Managing Director, overseeing daily operations and business development. Mukesh Kamath K serves as the Interim Chief Financial Officer and Nodal Officer, managing financial strategies and compliance.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Biocon Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Biocon Pharma Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has received approvals from the US FDA for various products, including Everolimus Tablets for Oral Suspension on January 12, 2026, and Tofacitinib Extended-Release Tablets on November 19, 2025. In the UK, Biocon Pharma Limited received a Good Manufacturing Practice (GMP) compliance certificate from the Medicines & Healthcare products Regulatory Agency (MHRA) on April 12, 2021, for its manufacturing facility at Biocon Park in Bengaluru. These approvals and certifications demonstrate the company's commitment to meeting international regulatory standards and expanding its global footprint.

2Emerging Markets

Biocon Pharma Limited has made strategic inroads into emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on affordable innovation has enabled it to address unmet medical needs in these regions. By obtaining World Health Organization (WHO) prequalification for certain products, Biocon Pharma Limited has facilitated access to these markets, ensuring that its high-quality medicines are available to a broader patient population.

3Geographic Strategy

Biocon Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Biocon Pharma Limited has achieved significant milestones with the US Food and Drug Administration (FDA). The company has received approvals for various products, including Everolimus Tablets for Oral Suspension on January 12, 2026, and Tofacitinib Extended-Release Tablets on November 19, 2025. Additionally, Biocon Pharma Limited's first US manufacturing facility in Cranbury, New Jersey, inaugurated in September 2025, is approved by the US FDA. These approvals and certifications underscore the company's commitment to meeting stringent regulatory standards and expanding its presence in the US market.

2WHO & EU GMP

Biocon Pharma Limited has demonstrated compliance with international manufacturing standards. The company received a Good Manufacturing Practice (GMP) compliance certificate from the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK on April 12, 2021, for its manufacturing facility at Biocon Park in Bengaluru. This certification reflects the company's adherence to stringent quality standards and its commitment to delivering high-quality pharmaceutical products to global markets.

3CDSCO & Indian Regulatory

Biocon Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Biocon Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry. While specific market share data is not available, the company's focus on affordable innovation and high-quality manufacturing positions it as a strong competitor in the global market. The recent expansion into the US market with the inauguration of its first US manufacturing facility in Cranbury, New Jersey, in September 2025, reflects a strategic move to enhance its competitive position.

2Key Differentiators

Biocon Pharma Limited differentiates itself through its commitment to affordable innovation and high-quality manufacturing. The company's integrated approach, encompassing both biosimilars and generic formulations, allows it to address a broad spectrum of therapeutic areas, including oncology, diabetes, and immunology. This comprehensive portfolio enables Biocon Pharma Limited to meet diverse patient needs and strengthen its position in the global pharmaceutical market.

3Strategic Position

Biocon Pharma Limited's strategic direction focuses on expanding its global footprint through the development and commercialization of biosimilars and generic formulations. The recent inauguration of its first US manufacturing facility in Cranbury, New Jersey, in September 2025, signifies a strategic move to strengthen its presence in the North American market. Looking ahead, the company aims to leverage its manufacturing capabilities and regulatory approvals to drive growth and deliver affordable, high-quality medicines to patients worldwide.

Buyer Due Diligence Brief — Evaluating Biocon Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Biocon Pharma Limited has established itself as a reliable supplier in the pharmaceutical industry. The company's manufacturing facilities are approved by various international regulatory bodies, including the US FDA, EMA, COFEPRIS, TGA, and ANVISA, indicating a consistent track record of compliance with global standards. The recent inauguration of its first US manufacturing facility in Cranbury, New Jersey, in September 2025, further demonstrates the company's commitment to expanding its manufacturing capabilities and ensuring a reliable supply chain.

2Certifications to Verify

Importers should verify the following certifications when considering Biocon Pharma Limited as a supplier:

FDA Approval: Confirm that the manufacturing facility is approved by the US Food and Drug Administration (FDA).

WHO-GMP Certification: Ensure that the manufacturing facility complies with World Health Organization (WHO) Good Manufacturing Practice (GMP) standards.

Frequently Asked Questions — Biocon Pharma Limited

How many pharmaceutical products does Biocon Pharma Limited export from India?

Biocon Pharma Limited exports 8 pharmaceutical products across 4 therapeutic categories. The top exports are Calcium ($43.3M), Rosuvastatin ($32.6M), Atorvastatin ($11.4M), Esomeprazole ($9.4M), Magnesium ($9.4M). Total export value is $112.4M.

What is Biocon Pharma Limited's total pharmaceutical export value?

Biocon Pharma Limited's total pharmaceutical export value is $112.4M, based on 2,250 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Biocon Pharma Limited cover?

Biocon Pharma Limited exports across 4 therapeutic categories. The largest are Vitamins & Supplements (46.8%, 2 products), Cardiovascular (39.2%, 2 products), Gastrointestinal (12.8%, 2 products).

Get Full Biocon Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Biocon Pharma Limited

Biocon Pharma Limited — Export Portfolio & Destination Treemap

Who is Biocon Pharma Limited? — Company Overview & Market Position

What Does Biocon Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Biocon Pharma Limited Therapeutic Categories — 4 Specializations